Metraipolis › archive › dc_33ed07586863

Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling study — Europe PMC PMID:41222853

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41222853
DOI: 10.1007/s10198-[numero omesso]-8
License (as archived): solo-consultazione
Archived: 2026-11-08T15:22:39.909Z
SHA-256 of the archived text: 4be52cdc6eb57c5342d2b42dab9004124483b28874ed26aa736a467ded0c640e
Stable URL of this page: https://metraipolis.com/documento/dc_33ed07586863

How to cite

Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling study — Europe PMC PMID:41222853 — Europe PMC (en), https://europepmc.org/article/MED/41222853 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_33ed07586863 (Metraipolis archive dc_33ed07586863, sha256 4be52cdc6eb57c5342d2b42dab9004124483b28874ed26aa736a467ded0c640e)

BibTeX

@misc{dc33ed07586863,
  title = {Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling study — Europe PMC PMID:41222853},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41222853},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_33ed07586863; sha256 4be52cdc6eb57c5342d2b42dab9004124483b28874ed26aa736a467ded0c640e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41222853. Agents can read the archived copy with the MCP tool read_document.